Skip to main content
Top
Literature
1.
go back to reference Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609CrossRefPubMed Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609CrossRefPubMed
2.
go back to reference Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30CrossRefPubMed Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30CrossRefPubMed
3.
go back to reference Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMed Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMed
4.
go back to reference Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.1007/s12288-017-0820-1 Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.​1007/​s12288-017-0820-1
5.
go back to reference Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53CrossRefPubMed Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53CrossRefPubMed
Metadata
Title
Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
Authors
Rahul Naithani
Tulika Seth
Nikhil Tandon
Jagdish Chandra
H. Pati
V. P. Choudhry
Publication date
01-04-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0858-0

Other articles of this Issue 2/2018

Indian Journal of Hematology and Blood Transfusion 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine